Brief: Adcendo Aps Under Agreement, Co Will Sponsor Phase 1B Clinical Trial And Msd Will Provide Pembrolizumab
26/05/2026 12:11
May 26 (Reuters) - Merck & Co Inc MRK.N: ADCENDO APS: CLINICAL COLLABORATION SUPPLY AGREEMENT WITH MSD TO EVALUATE ADCE-T02 IN COMBINATION WITH KEYTRUDA ADCENDO APS: UNDER AGREEMENT, CO WILL SPONSOR PHASE 1B CLINICAL TRIAL AND MSD WILL PROVIDE PEMBROLIZUMAB ADCENDO APS: EACH COS RETAIN ALL COMMERCIAL RIGHTS TO THEIR RESPECTIVE COMPOUNDS, INCLUDING AS MONOTHERAPY OR AS COMBINATION THERAPIES ADCENDO APS: ANTICIPATES DOSING FIRST PATIENT IN PHASE IB COMBINATION STUDY IN 2H 2026 Source text: ID:nCNW1MxFYa Further company coverage: MRK.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials